P78371 (TCPB_HUMAN) Homo sapiens (Human)

T-complex protein 1 subunit beta UniProtKBInterProSTRINGInteractive Modelling

535 aa; Sequence (Fasta) ; (Isoform 2); 14 identical sequences

Available Structures

49 Experimental Structures

DescriptionPDB IDOligo-stateRangeSeq id (%)Ligands
The beta-tubulin folding intermediate II Heteromer
P07437; P17987; P40227; P48643; P49368; P50990; P50991; Q99832;
4-531
100AF3;MG;ADP;
Human TRiC-PhLP2A-actin complex in the closed state Heteromer
P17987; P40227; P48643; P49368; P50990; P50991; P60709; Q99832; Q9H2J4;
2-528
100
Human TRiC complex in closed state with nanobody and tubulin bound Heteromer
P17987; P40227; P48643; P49368; P50990; P50991; Q13885; Q99832;
1-527
10016×ADP; 16×MG; 16×AF3;
Human TRiC complex in closed state with nanobody bound (Consensus Map) Heteromer
P17987; P40227; P48643; P49368; P50990; P50991; Q99832;
2-527
10016×ADP; 16×MG; 16×AF3;
CCT G beta 5 complex closed state 15 Heteromer
O14775; P17987; P40227; P48643; P49368; P50990; P50991; Q99832;
2-527
10016×ADP; 16×MG; 16×AF3;
CCT G beta 5 complex closed state 14 Heteromer
O14775; P17987; P40227; P48643; P49368; P50990; P50991; Q13371; Q99832;
2-527
10016×ADP; 16×MG; 16×AF3;
The beta-tubulin folding intermediate I Heteromer
P07437; P17987; P40227; P48643; P49368; P50990; P50991; Q99832;
6-531
100MG;ADP;AF3;
CCT G beta 5 complex closed state 0 Heteromer
P17987; P40227; P48643; P49368; P50990; P50991; Q13371; Q99832;
2-527
10016×ADP; 16×MG; 16×AF3;
CCT-G beta 5 complex closed state 7 Heteromer
O14775; P17987; P40227; P48643; P49368; P50990; P50991; Q13371; Q99832;
2-527
10016×ADP; 16×MG; 16×AF3;
CCT G beta 5 complex intermediate state Heteromer
P17987; P40227; P48643; P49368; P50990; P50991; Q99832;
2-527
10016×ADP;
CCT G beta 5 complex close state 11 Heteromer
O14775; P17987; P40227; P48643; P49368; P50990; P50991; Q13371; Q99832;
2-527
10016×ADP; 16×MG; 16×AF3;
CCT G beta 5 complex closed state 12 Heteromer
O14775; P17987; P40227; P48643; P49368; P50990; P50991; Q13371; Q99832;
2-527
10016×ADP; 16×MG; 16×AF3;
CCT G beta 5 complex closed state 2 Heteromer
O14775; P17987; P40227; P48643; P49368; P50990; P50991; Q13371; Q99832;
2-527
10016×ADP; 16×MG; 16×AF3;
CCT-G beta 5 complex closed state 6 Heteromer
O14775; P17987; P40227; P48643; P49368; P50990; P50991; Q99832;
2-527
10016×ADP; 16×MG; 16×AF3;
CCT G beta 5 complex closed state 13 Heteromer
O14775; P17987; P40227; P48643; P49368; P50990; P50991; Q13371; Q99832;
2-527
10016×ADP; 16×MG; 16×AF3;
The beta-tubulin folding intermediate IV Heteromer
P07437; P17987; P40227; P48643; P49368; P50990; P50991; Q99832;
6-531
100MG;ADP;AF3;
CCT-G beta 5 complex closed state 4 Heteromer
O14775; P17987; P40227; P48643; P49368; P50990; P50991; Q13371; Q99832;
2-527
10016×ADP; 16×MG; 16×AF3;
Human TRiC complex in closed state with nanobody Nb18, actin and PhLP2A bound Heteromer
P17987; P40227; P48643; P49368; P50990; P50991; P63261; Q99832; Q9H2J4;
2-527
10016×ADP; 16×MG; 16×AF3;
CCT G beta 5 complex closed state 9 Heteromer
O14775; P17987; P40227; P48643; P49368; P50990; P50991; Q13371; Q99832;
2-527
10016×ADP; 16×MG; 16×AF3;
The beta-tubulin folding intermediate III Heteromer
P07437; P17987; P40227; P48643; P49368; P50990; P50991; Q99832;
6-531
100MG;ADP;AF3;
CCT G beta 5 complex closed state 1 Heteromer
O14775; P17987; P40227; P48643; P49368; P50990; P50991; Q13371; Q99832;
2-527
10016×ADP; 16×MG; 16×AF3;
CCT G beta 5 complex closed state 10 Heteromer
O14775; P17987; P40227; P48643; P49368; P50990; P50991; Q99832;
2-527
10016×ADP; 16×MG; 16×AF3;
CCT G beta 5 complex closed state 3 Heteromer
O14775; P17987; P40227; P48643; P49368; P50990; P50991; Q99832;
2-527
10016×ADP; 16×MG; 16×AF3;
CCT G beta 5 complex best PhLP1 class Heteromer
O14775; P17987; P40227; P48643; P49368; P50990; P50991; Q13371; Q99832;
2-527
10016×ADP; 16×MG; 16×AF3;
CCT-G beta 5 complex closed state 8 Heteromer
O14775; P17987; P40227; P48643; P49368; P50990; P50991; Q99832;
2-527
10016×ADP; 16×MG; 16×AF3;
CCT G beta 5 complex closed state 5 Heteromer
O14775; P17987; P40227; P48643; P49368; P50990; P50991; Q13371; Q99832;
2-527
10016×ADP; 16×MG; 16×AF3;
cryo-EM structure of human TRiC-ADP-AlFx Heteromer
P17987; P40227; P48643; P49368; P50990; P50991; Q99832;
7-529
10016×ADP; 16×MG; 16×AF3;
Human TRiC-tubulin-S3 Heteromer
P07437; P17987; P40227; P48643; P49368; P50990; P50991; Q99832;
7-529
10016×ADP; 16×MG; 16×AF3;
cryo-EM structure of human TRiC-ATP-closed state Heteromer
P17987; P40227; P48643; P49368; P50990; P50991; Q99832;
7-529
100
Human TRiC-PhLP2A complex in the closed state Heteromer
P17987; P40227; P48643; P49368; P50990; P50991; Q99832; Q9H2J4;
5-526
10016×ADP; 16×MG; 16×AF3;
Human TRiC/CCT complex with reovirus outer capsid protein sigma-3 Heteromer
P03527; P17987; P40227; P48643; P49368; P50990; P50991; Q99832;
9-526
100ZN;
Human TRiC in ATP/AlFx closed state Heteromer
P17987; P40227; P48643; P49368; P50990; P50991; Q99832;
9-526
100
Cryo-EM structure of Human TRiC-ATP-open state Heteromer
P17987; P40227; P48643; P49368; P50990; P50991; Q99832;
10-526
100
Cryo-EM structure of human TRiC-NPP state Heteromer
P17987; P40227; P48643; P49368; P50990; P50991; Q99832;
10-526
100.0
Human TRiC open state Heteromer
P17987; P40227; P48643; P49368; P50990; P50991; Q99832;
10-526
100.0ADP;
Cryo-EM structure of human TRiC-tubulin-S2 Heteromer
P17987; P40227; P48643; P49368; P50990; P50991; Q99832;
10-526
10016×ATP;
cryo-EM structure of human TRiC-ADP Heteromer
P17987; P40227; P48643; P49368; P50990; P50991; Q99832;
10-526
10016×ADP;
hTRiC-hPFD Class3 Heteromer
O15212; O60925; P17987; P40227; P48643; P49368; P50990; P50991; P61758; Q99471; Q99832; Q9NQP4; Q9UHV9;
16-524
100
hTRiC-hPFD Class6 Heteromer
O15212; O60925; P17987; P40227; P48643; P49368; P50990; P50991; P61758; Q99471; Q99832; Q9NQP4; Q9UHV9;
16-524
100
hTRiC-hPFD Class5 Heteromer
O15212; O60925; P17987; P40227; P48643; P49368; P50990; P50991; P61758; Q99471; Q99832; Q9NQP4; Q9UHV9;
16-524
100
hTRiC-hPFD Class1 (No PFD) Heteromer
P17987; P40227; P48643; P49368; P50990; P50991; Q99832;
16-524
100
hTRiC-hPFD Class4 Heteromer
O15212; O60925; P17987; P40227; P48643; P49368; P50990; P50991; P61758; Q99471; Q99832; Q9NQP4; Q9UHV9;
16-524
100
hTRiC-hPFD Class2 Heteromer
O15212; O60925; P17987; P40227; P48643; P49368; P50990; P50991; P61758; Q99471; Q99832; Q9NQP4; Q9UHV9;
16-524
100
Human CCT:mLST8 complex Heteromer
P17987; P40227; P48643; P49368; P50990; P50991; Q99832;
17-524
100.0ADP;
Open state CCT-G beta 5 complex Heteromer
P17987; P40227; P48643; P49368; P50990; P50991; Q99832;
17-524
100.016×ADP;
Cryo-EM structure of human TRiC-tubulin-S1 state Heteromer
P17987; P40227; P48643; P49368; P50990; P50991; Q99832;
21-526
100.0ADP;
Human TRiC-PhLP2A complex in the open state Heteromer
P17987; P40227; P48643; P49368; P50990; P50991; Q99832; Q9H2J4;
24-522
10010×ADP;
Human TRiC complex in open state with nanobody bound Heteromer
P17987; P40227; P48643; P49368; P50990; P50991; Q99832;
23-521
100.016×MG; 16×ADP; 12×AF3;
Prefoldin-tubulin-TRiC complex Heteromer
O15212; O60925; P17987; P40227; P48643; P49368; P50990; P50991; P61758; Q99471; Q99832; Q9NQP4; Q9UHV9;
27-523
100ADP;

2 SWISS-MODEL models

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
7nvm.1.Kmonomer0.702-526
ADP;MG;AF3;100.00
8ba8.1.Ahomo-14-mer0.5318-526
BEF;23.11

2 SWISS-MODEL models built on isoform sequence

TemplateIsoformOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
Isoform 27nvm.1.Kmonomer0.711-479
MG;AF3;100.00
Isoform 27xok.1.Ahomo-14-mer0.521-478
21.94